Cover Image
市場調查報告書

沙烏地阿拉伯的醫藥品市場發展分析

Saudi Pharmaceutical Market Development Analysis

出版商 KuicK Research 商品編碼 310056
出版日期 內容資訊 英文 110 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
沙烏地阿拉伯的醫藥品市場發展分析 Saudi Pharmaceutical Market Development Analysis
出版日期: 2014年08月08日 內容資訊: 英文 110 Pages
簡介

具備現代的設備、設備,沙烏地阿拉伯在GCC(波灣合作理事會)地區中,醫療部門是技術發展最進步的國家之一,未來預計將成為急速成長的市場。沙烏地阿拉伯的醫藥品銷售額,與2013年的44億美元比較,預計2018年將70億美元。

本報告提供沙烏地阿拉伯的醫藥品市場相關調查、市場概要、藥價制度、罹患率、各市場區隔的市場分析、有希望的市場動態、法律規範及主要法規當局等相關分析、主要企業簡介,為您概述為以下內容。

第1章 沙烏地阿拉伯的醫藥品市場概要

  • 目前市場情況
  • 罹患率

第2章 醫藥品市場:各市場區隔

  • 品牌醫藥品
  • 學名藥
  • OTC

第3章 沙烏地阿拉伯的藥價制度

第4章 沙烏地阿拉伯的醫藥品市場力學

  • 中東的市場優勢
  • 國內醫藥品產業的支援
  • 有益的、制定的法律規範
  • OTC、學名藥的愛好
  • 進口依賴型的市場
  • 應解決課題

第5章 沙烏地阿拉伯的醫藥品市場未來展望

第6章 主要法規當局

  • National Drug and Poison Information Center
  • National Pharmacovigilance Center
  • Licensing Directorate
  • Executive Directorate of Laboratories
  • Executive Directorate of Inspection and Law Enforcement
  • Executive Directorate of Product Evaluation & Standard Setting

第7章 醫藥品市場上法律規範

  • 藥物認證流程(學名藥、生技藥品、放射性醫藥品及新化學物質)
  • 單株抗體及相關產品的品質指南
  • 調劑設備、籌備的法律
  • 生技仿製藥相關指南
  • 產品登記的前置調查
  • 醫藥品條碼的規格

第8章 競爭情形

  • SPIMACO
  • Tabuk Pharmaceuticals
  • Jamjoom Pharma
  • Julphar (Gulf Pharmaceutical Industries)
  • GSK
  • Pfizer
  • Novartis
  • Astra

圖表清單

目錄

The Saudi Arabia Pharmaceutical market has recorded significant growth over the years driven by various factors like increasing ageing population mostly in the above 60 years bracket, changing demographics and rise in the incidence of lifestyle diseases, increased spending power, result driven government initiatives to promote the growth of indigenous pharmaceutical companies. Inspite of the progress, the pharmaceutical sector in the Saudi Arabia is still in an emerging phase, and drug manufacturing is at a relatively nascent stage owing to many challenges, which need to be resolved. The Saudi pharmaceuticals market has accounted for more than to 50% of all pharmaceutical products sales in the GCC region.

Saudi Arabia relies substantially on imports of pharmaceutical products, primarily from Europe, to meet local demand as a result of insufficient domestic drug production and lack of indigenous research capabilities. Government is taking efforts to promote FDI in the pharmaceutical sector especially directed to help development of skills of local companies to manufacture patented medicines as well. Policies like free trade agreements have played a significant role in encouraging foreign investments. Increased penetration of the healthcare sector by insurance providers, price regulation guidelines to ensure uniformity in pricing and dedicated healthcare reforms, have further ensured growth of pharmaceutical market in recent years.

Saudi Arabia is expected to emerge as one of the fastest growing markets in future. The country is one of the most developed and technologically advanced medical sectors in the GCC Region with modern equipment and amenities. Pharmaceuticals products sales in Saudi Arabia are expected to surpass US$ 7 Billion by 2018 as compare to US$ 4.40 Billion 2013.

“Saudi Arabia Pharmaceutical Market Development Analysis” Report Highlight:

  • Market Overview
  • Drug Pricing system
  • Disease Prevalence
  • Market by segment: Generics, Branded & OTC
  • Favorable Market Dynamics
  • Regulatory Framework
  • Key Regulatory Enforcement Departments

Table of Contents

1. Saudi Arabia Pharmaceutical Market Overview

  • 1.1. Current Market Scenario
  • 1.2. Disease Prevalence

2. Pharmaceutical Market by Segment

  • 2.1. Branded Drugs
  • 2.2. Generic drugs
  • 2.3. OTC

    3. Saudi Arabia Drug Pricing System

4. Saudi Arabia Pharmaceutical Market Dynamics

  • 4.1. Market Dominance in Middle East
  • 4.2. Support to Domestic Pharmaceutical Industry
  • 4.3. Favorable & Established Regulatory Framework
  • 4.4. Preference for OTC & Generics Drugs
  • 4.5. Import Dependent Market
  • 4.6. Challenges to be Resolved

    5. Saudi Arabia Pharmaceutical Market Future Outlook

6. Key Regulatory Enforcement Departments

  • 6.1. National Drug and Poison Information Center
  • 6.2. National Pharmacovigilance Center
  • 6.3. Licensing Directorate
  • 6.4. Executive Directorate of Laboratories
  • 6.5. Executive Directorate of Inspection and Law Enforcement
  • 6.6. Executive Directorate of Product Evaluation & Standard Setting

7. Pharmaceutical Market Regulatory Framework

  • 7.1. Drug Approval Process (Generics, Biologicals, Radipharmaceuticals & New Chemical Entity)
  • 7.2. Monoclonal Antibodies and Related Products Quality Guideline
  • 7.3. Law of Pharmaceutical Establishments and Preparations
  • 7.4. Guidelines on Biosimilars
    • 7.4.1. Insulin
    • 7.4.2. Interferons
    • 7.4.3. Erythropoietin
    • 7.4.4. Granulocyte-Colony Stimulating Factor
    • 7.4.5. Human Growth Hormone
  • 7.5. Priority Review of Product Registration
  • 7.6. Drug Barcoding Specifications

8. Competitive Landscape

  • 8.1. SPIMACO
  • 8.2. Tabuk Pharmaceuticals
  • 8.3. Jamjoom Pharma
  • 8.4. Julphar (Gulf Pharmaceutical Industries)
  • 8.5. GSK
  • 8.6. Pfizer
  • 8.7. Novartis
  • 8.8. Astra

List of Figures

  • Figure 1-1: Saudi Arabia Pharmaceutical Market (US$ Billion), 2013-2018
  • Figure 1-2: Saudi Arabia Pharmaceutical Market by Segment (US$ Billion), 2013-2018
  • Figure 1-3: Saudi Arabia Pharmaceutical Market by Segment (%), 2013 & 2018
  • Figure 1-4: Factors Driving Growth in Saudi Pharmaceuticals Market
  • Figure 1-5: Burden of Communicable & Non Communicable Diseases in Saudi Arabia, 2012 & 2030
  • Figure 1-6: Leading Causes of Death in Saudi Arabia, 2011
  • Figure 2-1: Saudi Arabian Branded Drugs Market Value (US$ Billion), 2013-2018
  • Figure 2-2: Saudi Arabian Generics Drug Market Value (US$ Billion), 2013-2018
  • Figure 2-3: Saudi Arabian OTC Drug Market (US$ Billion), 2013-2018
  • Figure 3-1: Components of Drug Pricing System in Saudi Arabia
  • Figure 4-1: Share of Saudi Arabia in GCC Pharmaceuticals Market, 2013
  • Figure 4-2: Government Healthcare Expenditure (US$ Billion), 2012 & 2013
  • Figure 7-1: Saudi Arabia Drug Approval Process
  • Figure 7-2: Process for Designating A Drug For The Priority Review
  • Figure 7-3: Drug Barcoding Standard
  • Figure 7-4: Drug Barcoding Sample

List of Tables

  • Table 3-1: Pricing History and Legal Background in Saudi Arabia
  • Table 3-2: Drug Pricing for Generics
  • Table 3-3: Drug Pricing for Fixed Combinations
Back to Top